Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Autor: Yohann Loriot, Giulia Baciarello, Alberto Bossi, Laurence Albiges, Pierre Blanchard, Pernelle Lavaud, Clément Dumont, Karim Fizazi, Pierre-Olivier Bosset, Emeline Colomba, Soazig Nenan, Christophe Massard
Přispěvatelé: Institut Gustave Roussy (IGR), Département de médecine oncologique [Gustave Roussy], Oncologie gynécologique, Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Oncologie génito-urinaire, Department of Radiotherapy, UNICANCER
Rok vydání: 2020
Předmět:
Zdroj: Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, Elsevier, 2020, 18, pp.444-451. ⟨10.1016/j.clgc.2020.03.017⟩
ISSN: 1938-0682
1558-7673
DOI: 10.1016/j.clgc.2020.03.017⟩
Popis: Introduction Neoadjuvant chemotherapy with docetaxel and estramustine (DE) significantly improved relapse-free survival in patients with high-risk localized prostate cancer treated with androgen deprivation therapy (ADT) for 3 years and a local treatment in the GETUG-12 phase III trial. We sought to explore whether the addition of DE impacts long-term treatment-related side effects. Patients and Methods Patients randomized within the UNICANCER GETUG-12 trial at Gustave Roussy who were alive when ADT was discontinued were followed-up prospectively. Serum testosterone levels and clinical data regarding body weight, libido, erection, and cardio-vascular events were collected. Results Seventy-eight patients were included: 36 patients had been treated with ADT plus a local treatment and 42 with ADT+DE plus a local treatment. With a median follow-up of 5.9 years after ADT discontinuation, serum testosterone levels returned to normal values (> 200 ng/mL) for 57 (78%) of 72 evaluable patients, and 29 (43%) of 68 evaluable patients reported erections allowing intercourse without medical assistance. No impact of DE on testosterone level recovery, libido, quality of erections, and changes in body weight after ADT discontinuation was detected. The incidence of cardiovascular events was low and similar in both treatment arms. Conclusion Treatment with DE was not associated with excess long-term castration-related toxicity in men with high-risk localized prostate cancer. The relapse-free survival improvement seen with DE in GETUG-12 is likely not related to differed testosterone recovery.
Databáze: OpenAIRE
Externí odkaz: